What is the recommended Wolverine Stack (BPC-157 + TB-500) dosage?

Wolverine Stack (BPC-157 + TB-500) dosing varies by experience level. Beginners typically start at 500mcg daily, moderate users at 1000mcg daily, and aggressive protocols use 1500mcg 2x daily.

How do you reconstitute Wolverine Stack (BPC-157 + TB-500)?

Wolverine Stack (BPC-157 + TB-500) typically comes in 10mg vials. Add 2mL of bacteriostatic water to the vial. Use our free calculator for exact syringe units based on your desired dose.

What is the half-life of Wolverine Stack (BPC-157 + TB-500)?

The half-life of Wolverine Stack (BPC-157 + TB-500) is ~4-6 hours. This determines how frequently you need to dose for consistent blood levels.

Wolverine Stack (BPC-157 + TB-500)

Healing & RecoveryInjectionResearchGrade A~4-6 hours half-life

Accelerated HealingAnti-InflammatoryTissue RepairPeptide Blend6 weeks on / 2 weeks off

Benefits

Complete healing coverage: local + systemic

Synergistic repair mechanisms

One injection covers both peptides

Accelerates recovery from injuries and surgery

Reduces inflammation body-wide

Half-Life

~4-6 hours

Route

Injection

Frequency

Daily

Vial Sizes

10mg

BAC Water

2mL

Safety Grade

Grade A

Open Wolverine Stack (BPC-157 + TB-500) Dosage Calculator

Calculate exact syringe units for your vial and dose

About Wolverine Stack (BPC-157 + TB-500)

This pre-mixed blend combines the two most powerful healing peptides: BPC-157 (5mg) for targeted tissue repair and TB-500 (5mg) for systemic anti-inflammatory and regenerative effects. Together they provide both local and whole-body healing — BPC-157 promotes angiogenesis and tissue repair at the injury site, while TB-500 reduces inflammation throughout the body and promotes cell migration to damaged areas.

Who Should Consider Wolverine Stack (BPC-157 + TB-500)

Athletes recovering from soft tissue injuries (tendons, ligaments, muscle tears)
Post-surgical patients seeking accelerated wound healing
Individuals with chronic tendinopathy or repetitive strain injuries
Those seeking a convenient single-injection healing protocol combining BPC-157 and TB-500

How Wolverine Stack (BPC-157 + TB-500) Works

The Wolverine Stack combines two complementary healing mechanisms. BPC-157 acts locally by upregulating growth factor receptors (VEGFR2, FGFR1), promoting angiogenesis, accelerating tendon-to-bone healing, and modulating the nitric oxide system. TB-500 acts systemically by upregulating actin polymerization, promoting cell migration to damaged tissue, reducing inflammatory cytokines, and stimulating new blood vessel formation.

What to Expect

Weeks 1-2

Loading phase begins. Mild improvements in pain and inflammation may be noticed. BPC-157 begins local repair signaling while TB-500 reduces systemic inflammation.

Weeks 3-4

Noticeable improvement in pain levels, flexibility, and range of motion. Angiogenesis accelerates tissue repair at the injury site.

Weeks 5-6

Significant healing progress. Many users report substantially reduced pain and improved function. End of loading phase.

Weeks 7+

Transition to maintenance dosing. Continued healing support. Reload at full dose if a new injury occurs.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	500mcg	Daily
Moderate	1mg	Daily
Aggressive	1,500mcg	2x Daily

Note: Pre-mixed healing stack (5mg BPC-157 + 5mg TB-500). Dose is total mcg from vial. BPC handles local repair, TB-500 provides systemic anti-inflammation. The gold standard healing combo.

How to Inject Wolverine Stack (BPC-157 + TB-500)

Inject subcutaneously into the abdomen, thigh, or near the injury site. BPC-157 benefits from local injection near the injury. Rotate injection sites. Use an insulin syringe (29-31 gauge).

Cycling Protocol

On Period

6 weeks

Off Period

2 weeks

Loading phase: full dose daily for 4-6 weeks. Then maintenance: half dose every other day. The TB-500 component benefits from a loading protocol.

Pharmacokinetics

Half-Life

Bioavailability

SC: not established for the blend

Tmax

Not characterized

Data Confidence

low

Source: Estimated from component half-lives: BPC-157 plasma t1/2 ~30 min (functional ~4h), TB-500 plasma t1/2 ~5h. Blend half-life reflects the shorter-acting component for dosing purposes.

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Generally well-tolerated. Mild headache, nausea, or lightheadedness possible. Injection site reactions.

Contraindications

Active cancer or personal history of cancer — both components promote angiogenesis, which may support tumor vascularization
Pregnancy or breastfeeding — no safety data available
Active systemic infections — enhanced cell migration could theoretically spread pathogens
Known hypersensitivity to BPC-157, thymosin beta-4, or any formulation component

Drug Interactions

Anticoagulants (warfarin, heparin, DOACs) — both components promote angiogenesis and may increase bleeding risk
Anti-VEGF therapies (bevacizumab) — directly opposes the angiogenic mechanism of both peptides
Immunosuppressants — TB-500 modulates immune cell migration; effects on immunosuppressive therapy are unknown
NSAIDs — may partially counteract the inflammatory modulation; use is common but monitor healing progress